NGM Biopharmaceuticals (NGM) Stock Forecast, Price Target & Predictions
NGM Stock Forecast
NGM Biopharmaceuticals stock forecast is as follows: an average price target of $16.50 (represents a 971.43% upside from NGM’s last price of $1.54) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NGM Price Target
The average price target for NGM Biopharmaceuticals (NGM) is $16.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $4.00. This represents a potential 971.43% upside from NGM's last price of $1.54.
NGM Analyst Ratings
According to 4 Wall Street analysts, NGM Biopharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for NGM stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NGM Biopharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2022 | Steven Seedhouse | Raymond James | $4.00 | $3.41 | 17.30% | 159.74% |
| May 24, 2022 | - | Goldman Sachs | $29.00 | $13.64 | 112.61% | 1783.12% |
The latest NGM Biopharmaceuticals stock forecast, released on Oct 17, 2022 by Steven Seedhouse from Raymond James, set a price target of $4.00, which represents a 17.30% increase from the stock price at the time of the forecast ($3.41), and a 159.74% increase from NGM last price ($1.54).
NGM Biopharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.54 | $1.54 | $1.54 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of NGM Biopharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NGM Biopharmaceuticals's last price of $1.54. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 22, 2023 | B. Riley Securities | Buy | Buy | Hold |
| Oct 17, 2022 | Raymond James | - | Outperform | Downgrade |
| Oct 17, 2022 | Piper Sandler | - | Neutral | Downgrade |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
NGM Biopharmaceuticals's last stock rating was published by B. Riley Securities on Nov 22, 2023. The company gave NGM a "Buy" rating, the same as its previous rate.
NGM Biopharmaceuticals Financial Forecast
NGM Biopharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $2.25M | $18.18M | $7.91M | $8.29M | $20.95M | - | $18.57M | $16.77M | $21.57M | $19.77M | $23.48M | $19.75M | $24.36M | $31.08M | $21.57M | $25.34M | $25.55M |
| Avg Forecast | $104.18K | $31.43K | $52.38K | $87.30K | $558.20K | $2.46M | $3.30M | $6.14M | $6.77M | $7.06M | $13.40M | $14.95M | $20.20M | $22.65M | $22.55M | $22.49M | $21.97M | $20.45M | $21.78M | $23.19M | $17.07M | $17.87M | $21.69M | $21.59M |
| High Forecast | $104.18K | $31.43K | $52.38K | $87.30K | $558.20K | $2.46M | $3.30M | $6.14M | $6.77M | $7.06M | $13.40M | $14.95M | $20.20M | $22.65M | $22.55M | $22.49M | $21.97M | $20.45M | $21.78M | $23.19M | $17.07M | $17.87M | $21.69M | $21.59M |
| Low Forecast | $104.18K | $31.43K | $52.38K | $87.30K | $558.20K | $2.46M | $3.30M | $6.14M | $6.77M | $7.06M | $13.40M | $14.95M | $20.20M | $22.65M | $22.55M | $22.49M | $21.97M | $20.45M | $21.78M | $23.19M | $17.07M | $17.87M | $21.69M | $21.59M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 0.37% | 2.69% | 1.12% | 0.62% | 1.40% | - | 0.82% | 0.74% | 0.96% | 0.90% | 1.15% | 0.91% | 1.05% | 1.82% | 1.21% | 1.17% | 1.18% |
NGM Biopharmaceuticals's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.30M, with a low forecast of $3.30M, and a high forecast of $3.30M. NGM's average Quarter revenue forecast represents a 47.05% increase compared to the company's last Quarter revenue of $2.25M (Mar 23).
NGM Biopharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | $-31.03M | $-40.58M | $-50.19M | $-38.30M | $-47.71M | $-45.67M | $-31.15M | $-25.75M | $-27.37M | $-35.13M | $-25.99M | $-26.44M | $-28.14M | $-23.97M | $-17.38M | $-14.17M | $-8.97M | $-5.73M | $-6.31M |
| Avg Forecast | $-93.27K | $-28.14K | $-46.90K | $-78.16K | $-499.76K | $-2.20M | $-2.96M | $-5.49M | $-6.06M | $-6.32M | $-12.00M | $-33.53M | $-18.08M | $-20.28M | $-20.19M | $-29.70M | $-19.67M | $-18.30M | $-19.50M | $-16.74M | $-15.28M | $-16.00M | $-19.42M | $-13.18M |
| High Forecast | $-93.27K | $-28.14K | $-46.90K | $-78.16K | $-499.76K | $-2.20M | $-2.96M | $-5.49M | $-6.06M | $-6.32M | $-12.00M | $-26.82M | $-18.08M | $-20.28M | $-20.19M | $-23.76M | $-19.67M | $-18.30M | $-19.50M | $-13.39M | $-15.28M | $-16.00M | $-19.42M | $-10.54M |
| Low Forecast | $-93.27K | $-28.14K | $-46.90K | $-78.16K | $-499.76K | $-2.20M | $-2.96M | $-5.49M | $-6.06M | $-6.32M | $-12.00M | $-40.24M | $-18.08M | $-20.28M | $-20.19M | $-35.64M | $-19.67M | $-18.30M | $-19.50M | $-20.09M | $-15.28M | $-16.00M | $-19.42M | $-15.81M |
| Surprise % | - | - | - | - | - | 14.12% | 13.72% | 9.14% | 6.32% | 7.54% | 3.81% | 0.93% | 1.42% | 1.35% | 1.74% | 0.88% | 1.34% | 1.54% | 1.23% | 1.04% | 0.93% | 0.56% | 0.30% | 0.48% |
undefined analysts predict NGM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NGM Biopharmaceuticals's previous annual EBITDA (undefined) of $NaN.
NGM Biopharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | $-28.80M | $-38.26M | $-45.10M | $-34.58M | $-46.22M | $-45.97M | $-32.32M | - | $-28.86M | $-36.69M | $-27.54M | $-27.99M | $-29.77M | $-25.62M | $-19.11M | $-15.94M | $-10.92M | $-7.67M | $-8.27M |
| Avg Forecast | $-15.73M | $-26.60M | $-28.15M | $-34.29M | $-32.56M | $-35.13M | $-41.22M | $-42.82M | $-42.64M | $-48.99M | $-44.02M | $-35.27M | $-29.81M | $-27.74M | $-28.74M | $-31.48M | $-38.45M | $-30.34M | $-25.37M | $-18.41M | $-21.88M | $-22.87M | $-69.11M | $-17.27M |
| High Forecast | $-15.73M | $-26.60M | $-28.15M | $-34.29M | $-27.28M | $-35.13M | $-41.22M | $-42.82M | $-42.64M | $-48.99M | $-44.02M | $-28.22M | $-29.81M | $-27.74M | $-28.74M | $-25.18M | $-38.45M | $-30.34M | $-25.37M | $-14.73M | $-21.88M | $-22.87M | $-69.11M | $-13.82M |
| Low Forecast | $-15.73M | $-26.60M | $-28.15M | $-34.29M | $-44.00M | $-35.13M | $-41.22M | $-42.82M | $-42.64M | $-48.99M | $-44.02M | $-42.33M | $-29.81M | $-27.74M | $-28.74M | $-37.77M | $-38.45M | $-30.34M | $-25.37M | $-22.09M | $-21.88M | $-22.87M | $-69.11M | $-20.73M |
| Surprise % | - | - | - | - | - | 0.82% | 0.93% | 1.05% | 0.81% | 0.94% | 1.04% | 0.92% | - | 1.04% | 1.28% | 0.88% | 0.73% | 0.98% | 1.01% | 1.04% | 0.73% | 0.48% | 0.11% | 0.48% |
NGM Biopharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NGM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NGM Biopharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | $8.67M | $9.65M | $11.58M | $9.76M | $10.11M | $9.93M | $10.72M | - | $8.87M | $9.82M | $8.72M | $7.38M | $6.46M | $6.79M | $6.59M | $6.42M | $5.61M | $6.23M | $5.37M |
| Avg Forecast | $209.65K | $63.24K | $105.41K | $175.69K | $1.12M | $4.94M | $6.65M | $12.35M | $13.62M | $14.22M | $26.97M | $11.66M | $40.64M | $45.59M | $45.39M | $9.97M | $44.21M | $41.14M | $43.84M | $6.35M | $34.34M | $35.96M | $43.64M | $11.21M |
| High Forecast | $209.65K | $63.24K | $105.41K | $175.69K | $1.12M | $4.94M | $6.65M | $12.35M | $13.62M | $14.22M | $26.97M | $13.99M | $40.64M | $45.59M | $45.39M | $11.96M | $44.21M | $41.14M | $43.84M | $7.62M | $34.34M | $35.96M | $43.64M | $13.46M |
| Low Forecast | $209.65K | $63.24K | $105.41K | $175.69K | $1.12M | $4.94M | $6.65M | $12.35M | $13.62M | $14.22M | $26.97M | $9.32M | $40.64M | $45.59M | $45.39M | $7.97M | $44.21M | $41.14M | $43.84M | $5.08M | $34.34M | $35.96M | $43.64M | $8.97M |
| Surprise % | - | - | - | - | - | 1.75% | 1.45% | 0.94% | 0.72% | 0.71% | 0.37% | 0.92% | - | 0.19% | 0.22% | 0.88% | 0.17% | 0.16% | 0.15% | 1.04% | 0.19% | 0.16% | 0.14% | 0.48% |
NGM Biopharmaceuticals's average Quarter SG&A projection for Dec 23 is $1.12M, based on 3 Wall Street analysts, with a range of $1.12M to $1.12M. The forecast indicates a -87.04% fall compared to NGM last annual SG&A of $8.67M (Sep 23).
NGM Biopharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | $-0.35 | $-0.46 | $-0.55 | $-0.42 | $-0.57 | $-0.58 | $-0.41 | - | $-0.37 | $-0.48 | $-0.36 | $-0.40 | $-0.43 | $-0.38 | $-0.28 | $-0.24 | $-0.17 | $-0.13 | $-0.13 |
| Avg Forecast | $-0.19 | $-0.32 | $-0.34 | $-0.41 | $-0.39 | $-0.42 | $-0.50 | $-0.52 | $-0.52 | $-0.59 | $-0.53 | $-0.46 | $-0.36 | $-0.34 | $-0.35 | $-0.41 | $-0.46 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.28 | $-0.83 | $-0.28 |
| High Forecast | $-0.19 | $-0.32 | $-0.34 | $-0.41 | $-0.33 | $-0.42 | $-0.50 | $-0.52 | $-0.52 | $-0.59 | $-0.53 | $-0.46 | $-0.36 | $-0.34 | $-0.35 | $-0.41 | $-0.46 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.28 | $-0.83 | $-0.28 |
| Low Forecast | $-0.19 | $-0.32 | $-0.34 | $-0.41 | $-0.53 | $-0.42 | $-0.50 | $-0.52 | $-0.52 | $-0.59 | $-0.53 | $-0.46 | $-0.36 | $-0.34 | $-0.35 | $-0.41 | $-0.46 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.28 | $-0.83 | $-0.28 |
| Surprise % | - | - | - | - | - | 0.82% | 0.92% | 1.06% | 0.82% | 0.96% | 1.09% | 0.90% | - | 1.10% | 1.38% | 0.88% | 0.86% | 1.17% | 1.24% | 0.99% | 0.91% | 0.62% | 0.16% | 0.46% |
According to undefined Wall Street analysts, NGM Biopharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NGM previous annual EPS of $NaN (undefined).
NGM Biopharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| NKTX | Nkarta | $3.23 | $21.60 | 568.73% | Buy |
| LYEL | Lyell Immunopharma | $1.27 | $6.67 | 425.20% | Hold |
| PRLD | Prelude Therapeutics | $1.20 | $6.25 | 420.83% | Sell |
| SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
| TIL | Instil Bio | $27.63 | $78.25 | 183.21% | Hold |
| RZLT | Rezolute | $5.44 | $13.50 | 148.16% | Buy |
| KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
| ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
| NXTC | NextCure | $1.31 | $3.00 | 129.01% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| ASMB | Assembly Biosciences | $16.98 | $35.50 | 109.07% | Buy |
| FHTX | Foghorn Therapeutics | $8.24 | $16.33 | 98.18% | Buy |
| ACHL | Achilles Therapeutics | $1.03 | $2.00 | 94.17% | Buy |
| KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
NGM Forecast FAQ
Is NGM Biopharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, NGM Biopharmaceuticals (NGM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of NGM's total ratings.
What is NGM's price target?
NGM Biopharmaceuticals (NGM) average price target is $16.5 with a range of $4 to $29, implying a 971.43% from its last price of $1.54. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will NGM Biopharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for NGM stock, the company can go up by 971.43% (from the last price of $1.54 to the average price target of $16.5), up by 1783.12% based on the highest stock price target, and up by 159.74% based on the lowest stock price target.
Can NGM Biopharmaceuticals stock reach $2?
NGM's average twelve months analyst stock price target of $16.5 supports the claim that NGM Biopharmaceuticals can reach $2 in the near future.
What are NGM Biopharmaceuticals's analysts' financial forecasts?
NGM Biopharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $12.45M (high $12.45M, low $12.45M), average EBITDA is $-11.151M (high $-11.15M, low $-11.151M), average net income is $-152M (high $-146M, low $-163M), average SG&A $25.06M (high $25.06M, low $25.06M), and average EPS is $-1.832 (high $-1.769, low $-1.971). NGM's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $275.28K (high $275.28K, low $275.28K), average EBITDA is $-246K (high $-246K, low $-246K), average net income is $-105M (high $-105M, low $-105M), average SG&A $553.99K (high $553.99K, low $553.99K), and average EPS is $-1.265 (high $-1.265, low $-1.265).
Did the NGM's actual financial results beat the analysts' financial forecasts?
Based on NGM Biopharmaceuticals's last annual report (Dec 2022), the company's revenue was $55.33M, beating the average analysts forecast of $42.18M by 31.20%. Apple's EBITDA was $-166M, beating the average prediction of $-57.908M by 187.09%. The company's net income was $-159M, missing the average estimation of $-171M by -6.93%. Apple's SG&A was $40.52M, missing the average forecast of $66.45M by -39.03%. Lastly, the company's EPS was $-1.99, missing the average prediction of $-2.096 by -5.07%. In terms of the last quarterly report (Mar 2023), NGM Biopharmaceuticals's revenue was $2.25M, missing the average analysts' forecast of $6.14M by -63.39%. The company's EBITDA was $-50.194M, beating the average prediction of $-5.494M by 813.56%. NGM Biopharmaceuticals's net income was $-45.1M, beating the average estimation of $-42.818M by 5.33%. The company's SG&A was $11.58M, missing the average forecast of $12.35M by -6.20%. Lastly, the company's EPS was $-0.55, beating the average prediction of $-0.517 by 6.36%